Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

53.23
BATS BZX Real-Time Price
As of 11:09am ET
 +0.34 / +0.64%
Today’s Change
45.45
Today|||52-Week Range
71.60
-10.15%
Year-to-Date
Play Strong Defense With 3 Big Biotechs
Feb 07 / TheStreet.com
Why is Gilead (GILD) Stock Falling Today?
Jan 29 / Zacks.com
Is Gilead Sciences Finally Nearing a Bottom?
Feb 07 / MotleyFool.com
Roche's (RHHBY) Earnings Miss Estimates, Revenues Beat
Jan 29 / Zacks.com
Rx for Success: Play Defense With Big Biotech
Feb 07 / TheStreet.com
AbbVie Posts In-Line Earnings, Maintains 2016 Outlook
Jan 29 / Zacks.com
1 Company Gilead Sciences Should Consider Buying Right Now
Feb 06 / MotleyFool.com
Can Gilead (GILD) Keep the Earnings Streak Alive in Q4?
Jan 29 / Zacks.com
Why Halozyme Therapeutics Inc Plunged 51% in January
Feb 06 / MotleyFool.com
Merck launches hepatitis C drug price war
Jan 29 / FT.com
Gilead Sciences 2016 Guidance: Sandbagging Wall Street Again?
Feb 05 / MotleyFool.com
Instant Analysis: Can Merck Make Waves In the Crowded Hepatitis C Space?
Jan 29 / MotleyFool.com
Stocks Continue to Sink
Feb 05 / TheStreet.com
Merck's Hepatitis C Doublet Wins FDA Approval and Unveils Its Secret Weapon
Jan 29 / MotleyFool.com
The Zacks Analyst Blog Highlights: Biogen, Gilead, AbbVie, Intrexon and NewLink
Feb 04 / Zacks.com
AbbVie's (ABBV) 4Q Earnings In-Line With Estimates
Jan 29 / Zacks.com
Gilead (GILD) Beats Q4 Earnings Estimates, Gives 2016 View
Feb 03 / Zacks.com
Why Incyte's Shares Crashed 12% Today
Jan 28 / MotleyFool.com
Biotech Stock Roundup: Biogen, Amgen Top Estimates; Zika Virus Grabs Attention
Feb 03 / Zacks.com
3 Things to Watch in Gilead Sciences' Q4 Results
Jan 28 / MotleyFool.com
Why Regeneron Pharmaceuticals Shares Fell 23% in January
Feb 02 / MotleyFool.com
Will AbbVie (ABBV) Keep the Earnings Streak Alive in Q4?
Jan 27 / Zacks.com
Why Gilead Sciences Shares Tumbled 18% in January
Feb 02 / MotleyFool.com
Will Currency Volatility Keep Hurting Abbott's (ABT) Earnings?
Jan 27 / Zacks.com
Stocking Up on Cheap Biotech Stocks
Feb 02 / TheStreet.com
Amgen's Biosimilar of AbbVie's Humira under FDA Review
Jan 27 / Zacks.com
Gilead risks becoming victim of its own success
Jan 31 / FT.com
J&J investors urge activists to press for shake-up
Jan 27 / FT.com
Forget Biosimilars: It's This Threat That Could Dent AbbVie's Top Line
Jan 31 / MotleyFool.com
Global pharma groups reveal tie-up with universities
Jan 24 / FT.com
AbbVie: There Ain't No Stinkin' Biosimilar Threat
Jan 30 / MotleyFool.com
Shire deal demonstrates Kilsby's M&A acumen
Jan 15 / FT.com
Here's Why Johnson & Johnson's Sales Fell Last Year
Jan 30 / MotleyFool.com
Shire agrees $32bn takeover of Baxalta
Jan 11 / FT.com
Merck's HCV Drug Zepatier Gets FDA Nod; Sets Lower Price
Jan 29 / Zacks.com